HNGE

AI MemoPost-earnings T+3

Hinge Health

As of 2026-08-07/Post-earnings T+3/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-07 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

—

Key catalyst

Q2 earnings beat and raised FY2026 outlook • 2026-08-04

Base target: $102 / p=55% prob

Biggest risk

The stock now carries elevated execution expectations. Slower member conversion, margin compression, weaker client demand, or acquisition-integration problems could reverse the positive earnings reaction. Recent insider dispositions add a non-operating supply overhang. [#SEC-FORM4-2026-07-09] [#SEC-FORM4-2026-08-04]

Invalidation

Break below $72 or thesis failure.

What would change my mind?

The Q2 beat, stronger cash generation, raised FY2026 revenue midpoint, and continued client growth support a constructive post-earnings thesis. Cylinder Health adds a new care category and could broaden the platform if integration is effective.

Research note

Recommendation

—

Confidence

high

As of

2026-08-07

Base target

$102

p=55%

Bull target

$120

p=25%

Bear target

$72

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Expanded share-repurchase authorization
Cylinder Health acquisition and multi-condition expansion
Sustained client growth and margin execution

BearKey bullets

Analyst-target coverage and post-print estimate revisions are incomplete in the packet.
Cylinder Health integration and entry into gastrointestinal care create execution and capital-allocation risk.
Growth and 29% non-GAAP operating margin may not remain durable if member conversion, demand, or mix weakens.

WatchKey bullets

Q2 earnings beat and raised FY2026 outlook

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $102 (p=55%)

Target spread vs base: +18% / -29%

Scenario probabilities

Bull Target: $120 (p=25%)Base Target: $102 (p=55%)Bear Target: $72 (p=20%)

Commentary

Primary-source earnings evidence is strong and constructive. The live quote of $88.84 versus the August 6 anchor of $80.08 indicates an approximately 10.9% positive immediate reaction, but precise attribution and post-print analyst revisions remain limited. Social coverage is unavailable, so this remains constructive monitoring rather than a high-conviction re-rating call.

As of 2026-08-07 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Expanded share-repurchase authorization
Cylinder Health acquisition and multi-condition expansion
Sustained client growth and margin execution

Scenarios

Bull Target (Scenario probability)

$120 / p=25% prob

Base Target (Scenario probability)

$102 / p=55% prob

Bear Target (Scenario probability)

$72 / p=20% prob

Analysis 2026-08-07 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.72

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-04
Q2 earnings beat and raised FY2026 outlook
Q2 revenue rose 53% year over year to $212.8 million, non-GAAP operating margin reached 29%, free cash flow was $99.6 million, and the FY2026 revenue-guidance midpoint increased to $858 million. [#SEC-8K-2026-08-04]
Prob 100.00% • Move 8.00% • Priced-in 80.00%

Short-term Catalysts

Next few weeks

Expanded share-repurchase authorization
2026-08-04
The board approved a $300 million increase to the repurchase program, with transactions structured under Rule 10b-18 requirements. [#8-K-2026-08-04] [#SEC-8K-2026-08-04]
Prob 85% • Move 3% • Priced-in 70%

Long-term Catalysts

Months to a year

Cylinder Health acquisition and multi-condition expansion
2026-12-31
Hinge signed a definitive agreement to acquire Cylinder Health for $105 million in cash, expanding into virtual-first gastrointestinal care alongside its musculoskeletal and migraine programs. [#SEC-8K-2026-08-04]
Prob 60% • Move 12% • Priced-in 45%
Sustained client growth and margin execution
2026-12-31
Clients increased 24% year over year to 2,929 and LTM calculated billings increased 52%; sustaining conversion, growth, and profitability against the raised outlook remains the key longer-term validation point. [#SEC-8K-2026-08-04]
Prob 65% • Move 10% • Priced-in 55%

Risks

Analyst-target coverage and post-print estimate revisions are incomplete in the packet.
Cylinder Health integration and entry into gastrointestinal care create execution and capital-allocation risk.
Growth and 29% non-GAAP operating margin may not remain durable if member conversion, demand, or mix weakens.
Open-market sales by a 10% owner and CFO tax-withholding dispositions are supply signals, not evidence of operating performance. [#SEC-FORM4-2026-07-09] [#SEC-FORM4-2026-08-04]
Raised guidance may already be substantially reflected in expectations after the earnings reaction.

Peers

Symbol	Summary
HIMS	Closest digital-health platform reference, but not a direct musculoskeletal-care peer.
BSX	Large medtech benchmark useful for broad growth and valuation context; operating overlap is limited.
BLCO	Similar-size same-sector reference, but business-model overlap with Hinge's software-enabled care platform is weak.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-07

Loading AI feed…

Symbol

Summary

HIMS

Closest digital-health platform reference, but not a direct musculoskeletal-care peer.

BSX

Large medtech benchmark useful for broad growth and valuation context; operating overlap is limited.

BLCO

Similar-size same-sector reference, but business-model overlap with Hinge's software-enabled care platform is weak.